Lipid lowering

Lipid lowering refers to a therapeutic outcome and a broad pharmacological category rather than a single molecular target. It involves the use of various drugs to reduce the concentration of atherogenic lipoproteins in the blood, thereby decreasing the risk of atherosclerotic cardiovascular disease (ASCVD). This physiological effect is achieved by targeting multiple distinct proteins and pathways, including cholesterol biosynthesis in the liver, intestinal absorption of dietary lipids, and the regulated recycling of lipoprotein receptors (PubMed, PMID: 31054369). Elevated levels of low-density lipoprotein cholesterol (LDL-C) are a primary driver of plaque formation in arteries, and lipid-lowering interventions are foundational in preventing myocardial infarction and stroke (StatPearls, 2023). Major drug classes within this category include statins, ezetimibe, PCSK9 inhibitors, and fibrates, each addressing different components of the lipid profile. Because the term refers to a functional result rather than a specific receptor or enzyme, it is classified as a therapeutic class or clinical goal.

Other names

Hypolipidemic agentsAntihyperlipidemic therapyLipid-modifying agentsDyslipidemia therapy

Lipid lowering is achieved through several distinct molecular mechanisms: inhibition of the rate-limiting enzyme HMG-CoA reductase (statins), inhibition of the NPC1L1 intestinal cholesterol transporter (ezetimibe), inhibition of PCSK9 to increase LDL receptor density (monoclonal antibodies and siRNA), and activation of PPAR-alpha to modulate triglyceride metabolism (fibrates) (StatPearls, 2023; NIH, 2022).